Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX + bevacizumab vs FOLFOXIRI + bevacizumab in first-line metastatic colorectal cancer with ≥3 circulating tumor cells
2012-000846-37Phase 3Completed
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in metastatic colon cancer (mCRC) (2 arms), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2012-000846-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000846-37.